Biomea Fusion (NASDAQ: BMEA) shares rose 16.06% to $1.59 on Monday following the completion of enrollment in its COVALENT-211 Phase II clinical trial. The milestone advances the development of icovamenib for insulin-deficient type 2 diabetes.

The company announced that it has finished enrolling 64 participants across 18 sites for the randomized, double-blind, placebo-controlled study. Patients are randomized 2:1 to receive either icovamenib 100 mg once daily or placebo for 12 weeks as an add-on to stable background therapy. This is followed by a 40-week off-treatment period to assess glycemic control durability through Week 52. Biomea expects to report 26-week primary endpoint topline data in the first quarter of 2027.

Trial Design and Patient Profile

COVALENT-211 targets adult patients with insulin-deficient T2D who remain inadequately controlled on standard-of-care antihyperglycemic therapies. Eligible participants must be on a stable dose of one to three antihyperglycemic therapies for at least three months prior to screening.

Key inclusion criteria include:

• HbA1c levels between 7.5% and 10.5%
• Body mass index (BMI) of ≤32 kg/m²

Icovamenib is administered as an add-on to stable background therapy, which is maintained throughout the study unless rescue therapy is required.

Parallel Development in GLP-1 Non-Responders

Enrollment remains ongoing for COVALENT-212, which evaluates icovamenib in T2D patients not achieving glycetic targets despite GLP-1 based therapy. The company expects to complete enrollment before year-end, with 26-week topline primary endpoint data anticipated in the second quarter of 2027.

COVALENT-212 eligibility requires:

• Stable dose of GLP-1-based therapy for at least three months
• HbA1c levels between 7.0% and 10.5%
• BMI between 25 and 45 kg/m²

Participants may receive up to two additional background therapies, such as metformin and/or an SGLT2 inhibitor.

What the Numbers Show

Both trials build on Phase II COVALENT-111 data, which demonstrated durable glycemic improvements after short treatment courses. In the 52-week analysis:

The divergence in HbA1c reduction between the two subgroups—1.8% for GLP-1 non-responders versus 1.5% for severe insulin-deficient patients—suggests distinct efficacy profiles across high-need T2D populations. Both groups showed increased C-peptide levels off-treatment, supporting the proposed mechanism of beta-cell function improvement. No treatment-related serious adverse events were observed during the 52-week observation period.

Biomea Fusion (NASDAQ: BMEA) reported a second-quarter earnings per share (EPS) of $(0.12), surpassing analyst expectations and demonstrating a marked improvement in its financial trajectory. The company’s actual loss per share was narrower than the consensus estimate of $(0.22), beating the forecast by 45.45 percent. This performance signals potential stabilization in operational costs or revenue generation, offering a positive signal to investors monitoring the biopharmaceutical firm’s path toward profitability.

The results also reflect a substantial year-over-year improvement. Compared to the same period last year, when Biomea Fusion reported losses of $(0.51) per share, the current quarter’s figure represents a 76.47 percent reduction in losses. This significant narrowing suggests that management’s strategic initiatives to control burn rates or advance pipeline milestones are beginning to yield measurable financial benefits, even as the company continues to operate at a net loss.

Key Financial Metrics

What the Numbers Show

The divergence between the reported EPS and the analyst estimate is the most material takeaway from this filing. Beating a loss estimate by nearly half indicates that market participants may have been overly pessimistic regarding Biomea Fusion’s near-term cash flow dynamics or operational efficiency. Furthermore, the 76.47 percent improvement year-over-year highlights a deceleration in the rate of capital consumption. While the company remains unprofitable, the trajectory of shrinking losses provides a clearer view of the runway available for future clinical development and commercialization efforts without immediate need for dilutive financing.